|Year : 2016 | Volume
| Issue : 1 | Page : 31-36
Antischistosomal activity of Mirazid in experimental schistosomiasis mansoni: exploring the controversy
Mohammad A Al-Kazzaz MSc , Mona H El-Sayad, Sahar A Abu-Helw
Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, Egypt
|Date of Submission||14-Dec-2015|
|Date of Acceptance||22-Mar-2016|
|Date of Web Publication||25-Oct-2016|
Mohammad A Al-Kazzaz
27 Street, 15 Al-Awayed, Alexandria
Source of Support: None, Conflict of Interest: None
Mirazid (MZD) was licensed in Egypt for treatment of schistosomiasis in the year 2002; the drug gained much attention experimentally and clinically, with conflicting views on its efficacy.
The study aimed to evaluate MZD anti-schistosomal activity in an animal model at a selected dose.
Materials and methods
Swiss albino mice (n=36) were infected with Schistosoma mansoni and divided into two equal groups of 18 mice each: group 1 was the nontreated infected control group given only the vehicle; gourp 2 was infected and treated with MZD at a dose of 500 mg/kg for 5 days per os 7 weeks postinfection. Efficacy of the drug was assessed parasitologically with fecal egg counts evaluated every other day until the animal was euthanized at 1, 2, and 4 weeks post-treatment (WPT); worm burden, tissue egg count and oogram pattern were studied at 1, 2, and 4 WPT.
MZD reduced fecal egg counts in infected mice (69.6%) and reduced total worm load (71.9%) and tissue egg counts in the intestine and the liver (66 and 77.4%, respectively) at 4 WPT. The drug changed oogram pattern with progress of treatment.
MZD has moderate antischistosomal activity in animal models.
Keywords: mice, mirazid, oogram pattern, Schistosoma mansoni, tissue egg count, worm burden
|How to cite this article:|
Al-Kazzaz MA, El-Sayad MH, Abu-Helw SA. Antischistosomal activity of Mirazid in experimental schistosomiasis mansoni: exploring the controversy. Parasitol United J 2016;9:31-6
|How to cite this URL:|
Al-Kazzaz MA, El-Sayad MH, Abu-Helw SA. Antischistosomal activity of Mirazid in experimental schistosomiasis mansoni: exploring the controversy. Parasitol United J [serial online] 2016 [cited 2021 May 12];9:31-6. Available from: http://www.new.puj.eg.net/text.asp?2016/9/1/31/192993
| Introduction|| |
Mirazid (MZD) is a natural pharmaceutical preparation introduced into the Egyptian market by Pharco Pharmaceuticals (Alexandria, Egypt) in the form of soft gelatin capsules since 2002. Each capsule contains 300 mg of the purified oleoresin extract of Commiphora molmol (Myrrh) . The Egyptian drug authority in the Egyptian Ministry of Health registered this product for treatment of schistosomiasis (Reg. No. 21655/2002) . The antischistosomal properties of MZD were investigated, and reviewed both experimentally and clinically with controversy regarding its efficacy .
In humans, the efficacy of MZD as an anti-schistosomal drug was evaluated clinically with positive results ,,,,,. All in all, they enrolled 365 schistosomiasis patients (adults and children) and treated them with MZD at a dose of 10–11.5 mg/kg for 3–6 days. The cure rate, evaluated parasitologically (disappearance of fecal eggs) by Kato–Katz and rectal snip techniques at 2–3 months after treatment, was 80.7–100%. The drug proved to have nonsignificant side effects. The drug was tested by other researchers, with disappointing results. It showed little or no beneficial activity as reported by Barakat et al. , Botros et al. , and Osman et al. , who altogether enrolled 206 patients (adults or children) treated with MZD at a dose of 300–600 mg daily for 3–6 days. The drug showed a cure rate that ranged from 3.7 to 15.6 % at 3–8 WPT.
Such controversy prompted us to study the efficacy of MZD experimentally as there are many parasitological parameters other than fecal egg counts.
| Materials and methods|| |
The study was conducted at the Department of Parasitology, Medical Research Institute (MRI), Alexandria University, Alexandria, Egypt, during the period from 21 July 2013 to 14 October 2014.
The study included 36, 8-week-old female Swiss albino mice of the CD-1 strain weighing 20±2 g, obtained from the animal house of the MRI, Alexandria University, Alexandria, Egypt. Laboratory-bred Biomphalaria alexandrina snails infected with miracidiae of the Egyptian (CD) strain of Schistosoma mansoni were obtained from the Schistosome Biologic Supply Center, Theodore Bilharz Research Institute, Cairo, Egypt. MZD capsules were obtained as free medical samples from Pharco Pharmaceuticals, Batch No: 296. Each capsule (300 mg) was emptied in a flask containing 3 ml of 4% Cremophor EL used as the vehicle for drug administration.
Infected B. alexandrina snails were washed with dechlorinated water and kept in an aerated aquarium (using an electric pump) in a dark place (by covering the glass bath with a black plastic bag) . Before use, snails were rinsed gently with a small volume of water to remove feces and other debris, then resuspended in water (1 ml/snail) and left uncovered in a glass test tube under white fluorescent light for a period of 30–60 min to release cercariae ([Figure 1];1). After shaking gently to ensure homogenous distribution of cercariae, 1 ml of cercarial suspension was pipetted and placed on glass slides; a drop of iodine was added to each slide to kill and stain the cercariae ([Figure 1];2). With the aid of a stereobinocular microscope, the number of cercariae was counted in each slide. Generally, three counts were made in 3 ml cercarial suspension and the average number per 1 ml was calculated.
|Figure 1 Steps of mice infections: (1) cercarial shedding; (2) cercarial count; (3) cercarial inoculation.|
Click here to view
Mice were infected using the paddling technique according to Smithers and Terry . Each mouse was exposed separately to about 100 S. mansoni cercariae ([Figure 1];3). Infected mice were then segregated in separate stainless steel wire mesh cages, and received a standard well-balanced diet and water. The mice were housed in a room under controlled environmental temperature. Stool examination was performed 50 days after cercarial infection to determine the presence of S. mansoni eggs.
MZD was administered at a dose of 500 mg/kg for 5 days per os, 7 WPI. Each mouse required 0.1 ml solution to reach a dose of 500 mg/kg. The dose was selected as specified by Botros et al.  and Massoud et al.  and is four-fold the therapeutic dose in mice (125 mg/kg) based on Food and Drug Administration guidelines by converting the human dose to those for experimental animals.
Evaluation of drug efficacy was based on the following parasitological parameters: (a) fecal eggs were counted every other day starting 2 days post-treatment (PT) and continued until the mice were sacrificed at 1, 2, and 4 weeks post-treatment (WPT) according to Sewify ; (b) for recovery of adult worms, the perfusion technique was carried out according to Smithers and Terry . The collected worms were counted to estimate the total worm count and differentiation into male and female worms; (c) tissue egg counts in the liver and intestine were calculated according to Cheever . Tissues were frozen until examination; (d) the oogram pattern (percentage of egg developmental stages) was studied according to the method of Pellegrino et al. .
The data were coded, collected, tabulated, and analyzed using the independent two-sample t-test with Minitab statistical software, version 14 (Minitab Inc., Pennsylvania State College, Pennsylvania, USA). Descriptive statistics were expressed as arithmetic mean ± SD as measures of central tendency and dispersion, respectively. The level of significance (P<0.05) was considered statistically significant. The change% in each parasitological parameter was calculated according to the following equation.
The study protocol was reviewed and approved by the Ethics Committee of the MRI, University of Alexandria.
| Results|| |
MZD resulted in a nonsignificant reduction in the number of S. mansoni eggs in the stool of the treated group (4.5%) 1 WPT followed by significant reduction of 39.5 and 69.6% at 2 and 4 WPT, respectively, compared with the nontreated infected group ([Figure 2] and [Table 1]). MZD significantly reduced the total worm burden by 34, 50, and 72% at 1, 2, and 4 WPT, respectively ([Table 1]). The number of male and female worms decreased, males being more affected than females at 1 and 2 WPT with significant reduction of 37.9 and 56.7% compared with 25.3 and 36.8%, respectively. At 4 WPT, there was significant reduction of both male (75.1%) and female worms (60%) ([Table 1]).
|Figure 2 Egg counts in the stool of MZD-treated Schistosoma mansoni-infected mice compared with nontreated infected mice. MZD, mirazid.|
Click here to view
|Table 1 Effect of mirazid on fecal egg counts, total worm burden, and worm sex in Schistosoma mansoni-infected treated mice compared with nontreated infected mice according to WPT|
Click here to view
MZD produced significant reduction in the tissue egg counts in the intestine (29.1–66%) throughout the follow-up weeks. Reduction in the hepatic tissue egg load was nonsignificant at 1 WPT (22.1%), and became significant in the second and fourth week (42.7 and 77.4%) ([Table 2]). In the treated group the percentage of dead eggs at 1, 2, and 4 WPT and the mean percentage of mature eggs at 2 and 4 WPT were significantly increased compared with the values in nontreated infected mice. At 4 WPT, more than 50% of the eggs were mature, which denotes interruption in egg laying as the number of immature eggs decreased with increase in the number of mature and dead eggs.
|Table 2 Effect of mirazid on the mean tissue egg counts and the oogram pattern in Schistosoma mansoni-infected mice at 1, 2, and 4 WPT compared with nontreated mice|
Click here to view
| Discussion|| |
MZD was tested in in vitro studies by Hassan et al. , Sharaf , and Bakr et al.  in which they exposed S. mansoni worms to various concentrations of MZD from 100 to 400 µg/ml. The drug elicited maximal somatic muscle contraction at the highest concentration and a strong lethal effect occurred after 24 h exposure. Karamustafa et al.  verified the lethal effects of MZD on adult worms and larvae of S. mansoni (IC50=7.18–32.69 μg/ml).
In our in vivo study, MZD was tested experimentally in S. mansoni-infected mice at a selected dose of 500 mg/kg for 5 days, producing a significant gradual decrease in the total number of worms up to 72% by the fourth WPT but did not abolish the infection. Using the same dose for 5 days, Massoud et al.  had reported a 98% reduction in total worm load 45 days post-infection, whereas Botros et al.  found that the drug showed only 9% total worm reduction. Bakr et al.  also used the same dose of 500 mg/kg but for 3 days and obtained 82.5% reduction in the total worm load at 1 month PT. Hamed and Hetta  reported that a dose of 600 mg/kg for 3 days led to 81.1% worm reduction 27 days PT. Shorter periods of effective response to MZD treatment were reported by Badria et al.  who used the drug at a dose of 500 mg/kg twice a day for 3 days and recorded 75% worm burden reduction after 5 days PT. Lotfy et al.  also used a dose of 600 mg/kg for 5 days with significant worm load reduction (69.3%) at 4 WPT. El-Gamal et al.  studied the effect of a single dose administered 6 weeks after infection and the drug eradicated 58.6% of total worms at 2 WPT. However, contradictory results reported ,,,,,,, showed low worm burden reduction rates, not more than 10%, in S. mansoni, S. haematobium, and S. japonicum-infected mice or hamsters treated with oral doses of MZD that varied from 250 to 500 mg/kg for 2–5 days. Such controversial results are expected because of variations in drug dosage and/or number of days of administration.
In the present work, the number of male and female worms decreased, males being more affected than females at 1 and 2 WPT with significant reduction of 37.9 and 56.7% compared with 25.3 and 36.8%, respectively. At 4 WPT, there was significant reduction in the number of both male and female worms (66%). These results apparently conform with those of Bakr et al.  for male worms (75.1%) but not for female worms (83.8%) from MZD-treated mice 4 WPT with 500 mg/kg for 3 days; but Botros et al.  found nonsignificant reduction in male and female worms at 2 WPT (12.4 and 24.5%), respectively.
Relative to the decrease in the number of worms the drug resulted in nonsignificant reduction in the number of S. mansoni eggs in the stool (4.5%) at 1 WPT, but it caused significant reduction (39.6 and 69.6%) at 2 and 4 WPT compared with the non-treated infected group. Another experimental report  recorded 6.6% followed by 44% reduction in fecal egg counts at 2 and 4 WPT, respectively, using 500 mg/kg MZD for 5 days. In contrast, using a higher dose of 600 mg/kg for 6 days, 97% reduction in fecal egg counts was induced after 4 weeks of MZD therapy .
MZD resulted in significant reduction in tissue egg counts in the intestines (48.9–66%) throughout the 4 WPT follow-up in our study. Nonsignificant reduction in the hepatic tissue egg load was observed at 1 WPT (22.1%) but the drug was able to significantly reduce the egg count in the second and fourth WPT (42.7 and 77.4%, respectively). Higher tissue egg count reduction of 98.2 and 97% in the intestinal and hepatic tissue egg counts, respectively, was recorded at 5 WPT . In contrast, another research  recorded a lower percentage reduction of 41% and 28.9% in hepatic and intestinal tissue egg counts at 4 WPT and with a similar MZD dose of 500 mg/kg, but for 3 days. Other studies , found nonsignificant change in both intestinal and hepatic tissue egg loads at 2 WPT with a dose of MZD 300 or 500 mg/kg for 3 or 5 days, and examined 7 WPI.Regarding the oogram pattern, MZD resulted in significant increase in the percentage of dead eggs at 1, 2, and 4 WPT and in the mean percentage of mature eggs at 2 and 4 WPT compared with the nontreated infected mice. At 4 WPT, more than 50% of the eggs were mature. As the female worm starts oviposition 30 days after infection and the laid immature eggs take about 6 days to mature, a reduction in the number of immature eggs and/or increase in mature or dead eggs indicate that the chemical examined interfered with oviposition. Massoud et al.  attributed the changes in the oogram pattern produced by MZD to an early interruption of egg laying in the intestinal wall or the blocking of oviposition development. Also, Badria et al.  reported that MZD caused separation of male and female-coupled worms and shifting of female worms from their normal habitat to the liver resulting in progressive reduction of immature eggs deposited in the wall of the small intestine with an increase in mature eggs (93%), but they did not report on dead eggs. These results do not coincide with those of other studies ,,, which found an absence of oogram alterations after MZD treatment of mice or hamsters.
| Conclusion|| |
MZD showed moderate (72%) antischistosomal activity in the animal model at the assigned dose after treatment.
Many thanks to Dr Rashad Abdulghani, Department of Parasitology, Faculty of Medicine and Health Sciences, Sana’a University, Sana’a, Yemen, for his support in the practical part of this work.
MA Al Kazzaz suggested the idea of this work, searched the literature, statistically analyzed the data, and prepared the manuscript; MH El-Sayad supervised the study and designed the experiments and shared in the revision of the manuscript; SA Abu Helw shared in the supervision of the study, data analysis, and revision of the manuscript.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Botros S, William S, Ebeid F, Cioli D, Katz N, Day TA, Bennett JL. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 2004; 71:206–210.
Aziz M. Study of the efficacy of Nitazoxanide, Myrrh total oil and Mirazid in comparison with Praziquantel in experimental schistosomiasis mansoni
[MSc thesis]. Department of Parasitology, Medical Research Institute, University of Alexandria; 2014.
Abdul-Ghani RA, Loutfy N, Hassan A. Myrrh and trematodoses in Egypt: an overview of safety, efficacy and effectiveness profiles. Parasitol Int 2009; 58:210–214.
Massoud AM, Salama O, Bennett JL. The therapeutic efficacy of a new schistosomicidal drug, derived from Myrrh in active intestinal schistosomiasis complicated with hepatosplenomegally. Parasitol Int 1998; 47(Suppl 1):125.
Gaballah M, El-Gilany A, El-Shazly A, Motawea SS. Control of schistosomiasis in a rural area using a new safe effective herbal treatment. J Environment Sci 2001; 21:63–84.
Sheir Z, Nasr AA, Massoud A, Salama O, Badra GA, El-Shennawy H et al.
A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 2001; 65:700–704.
Abo-Madyan AA, Morsy TA, Motawea SM. Efficacy of Myrrh in the treatment of schistosomiasis (haematobium
) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol 2004; 34:423–446.
Soliman OE, El-Arman M, Abdul-Samie ER, El-Nemr HI, Massoud A. Evaluation of myrrh (Mirazid) therapy in fascioliasis and intestinal schistosomiasis in children: immunological and parasitological study. J Egypt Soc Parasitol 2004; 34:941–966.
Massoud AM, El-Sherbini ET, Mos N, Saleh NM, Abouel-Nour MF, Morsy AT. Mirazid in treatment of three zoonotic trematodes in Beni-Sweif and Dakhalia Governorates. J Egypt Soc Parasitol 2010; 40:119–134.
Barakat R, Elmorshedy H, Fenwick A. Efficacy of myrrh in the treatment of human schistosomiasis mansoni
. Am J Trop Med Hyg 2005; 73:365–367.
Botros S, Sayed H, El-Dusoki H, Sabry H, Rabie I, El-Ghannam M et al.
Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni
-infected school children and households. Am J Trop Med Hyg 2005; 72:119–123.
Osman MM, El-Taweel HA, Shehab AY, Farag HF. Ineffectiveness of myrrh-derivative Mirazid against schistosomiasis and fascioliasis in humans. East Mediterr Health J 2010; 16:932–936.
Liang. YS, Bruce JI, Boyd DA. Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proceedings of the First Sino-American Symposium; 1987. pp. 34–48.
Smithers SR, Terry RJ. The infection of laboratory hosts with cercariae of Schistosoma mansoni
and the recovery of the adult worms. Parasitology 1965; 55:695–700.
Massoud AM, El Ebiary FH, Abou-Gamra MM, Mohamed GF, Shaker SM. Evaluation of schistosomicidal activity of myrrh extract: parasitological and histological study. J Egypt Soc Parasitol 2004; 34(Suppl):1051–1076.
Sewify MM. Study of some plant essential oil compounds against Schistosoma mansoni
infection in experimental animals [MSc thesis]. Department of Parasitology and Medical Entomology, High Institute of Public Health, University of Alexandria; 2009.
Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting S. mansoni
eggs in tissues. Bull World Health Organ 1968; 39:328–331.
Pellegrino J, Oliveira CA, Faria J, Cunha AS. New approach to the screening of drugs in experimental Schistosomiasis mansoni
in mice. Am J Trop Med Hyg 1962; 11:201–215.
Hassan M, El-Motaiem M, Afify H, Abaza B, El-Shafei M, Massoud AM. In vitro
effect of Mirazid on Schistosoma mansoni
worms. J Egypt Soc Parasitol 2003; 33:999–1008.
Sharaf OF. The effect of antischistosome drugs on schistosomes and the immune response of their hosts [MD thesis]. Institute of Biomedical Life Sciences, Division of Infection and Immunity, University of Glasgow; 2004.
Bakr M, El-Sobky M, Harba N, Hassb El-Nabi S. Study of in vivo
and in vitro
effects of Mirazid on murine Schistosomiasis mansoni
. J Schistosomiasis Infect Endem Dis 2009; 31:35–49.
Karamustafa SD, Mansour N, Demirci B, Ankli A, Başer KHC, Bickle Q et al. In vitro
effect of Myrrh extracts on the viability of Schistosoma mansoni
larvae. Planta Med 2011; 77:1317.
Hamed MA, Hetta MH. Efficacy of Citrus reticulata
and Mirazid in treatment of Schistosoma mansoni
. Mem Inst Oswaldo Cruz 2005; 100:771–778.
Badria F, Abou-Mohamed G, El-Mowafy A, Massoud A, Salama O. Mirazid: a new antischistosomal drug. Pharm Biol 2001; 93:127–129.
Lotfy WM, Nageh AM, Hussein NA, Hassan AA. Application and evaluation of a molecular approach for detection of the schistosomicidal effect of Mirazid® (myrrh) in the murine model. J Adv Res 2013; 4:563–567.
El-Gamal RL, Farghaly AM, El-Gindy AM, Matter MA, Mohammed SA, Abo-El-Maaty DA et al.
Monitoring of some Th1 and Th2 cytokine patterns after Praziquantel and Mirazid treatment in experimental mansoniasis. Egypt J Med Sci 2009; 30:122–135.
Guirguis FR, Mahmoud SS. On the efficacy of a new antischistosomal drug (Mirazid) against Schistosoma haematobium
and S. mansoni
, an in vivo
study. J Egypt Ger Soc Zoo 2003; 42(D):89–98.
Ebeid F, El-Lakkany N, Seif El-Din S, Sabra A, Nosseir M, Botros S. Effect of Mirazid against different developmental stages of Schistosoma mansoni
worms and its safety in normal mice. Egypt J Schistosomiasis Infect Endem Dis 2005; 27:15–24.
Emam MH, Abd El-Rahman M, Gamil IS, Muselhy MA. Studies on the effect of antioxidant Selenium-ACE after treatment with Praziquantel and Mirazid in Schistosoma mansoni
infected mice. Egypt J Hosp Med 2009; 37:709–725.
Ramzy F, Mahmoud S, William S. Further assessment of Mirazid as antischistosomal drug in experimental schistosomiasis hematobium
. Pharm Biol 2010; 48:775–779.
Abdul-Ghani R, Loutfy N, Sheta M, Hassan A. Efficacy of low-dose myrrh protocols in the treatment of experimental schistosomiasis mansoni
: hepatic improvement without parasitologic cure. Res Rep Trop Med 2010; 1:65–71.
El-Kott AF, Mohammed RT, Ismail NR. Efficacy of garlic and Mirazid in treatment of the liver granuloma in mice infected with Schistosoma mansoni
. Res J Parasitol 2011; 10:1–9.
El-Malky MA, Lu SH, El-Beshbishi SN, Saudy NS, Ohta N. Effect of Mirazid in Schistosoma japonicum
-infected mice: parasitological and pathological assessment. Parasitol Res 2013; 112:373–377.
Abo-El-Maatti DM, Atteya FM, Ghattas MH. Oxidative stress and vascular endothelial growth factor in experimental animal model of Schistosoma mansoni
treated with myrrh or praziquantel. Egypt J Biochem Mol Biol 2006; 24:25–39.
[Figure 1], [Figure 2]
[Table 1], [Table 2]